Baddi — part of the Baddi–Barotiwala–Nalagarh (BBN) belt in Himachal Pradesh — is India’s largest pharmaceutical manufacturing cluster. Buying an established, compliant unit here means taking over a working plant, a trained workforce, and a live client book inside that cluster, instead of spending 18–24 months building one from scratch.

For a manufacturing purchase, the postcode is not a detail; it is a large part of the value. Baddi removes the problems a tier-2 industrial zone would create on day one:

• A concentrated supply chain. Bulk-drug and excipient suppliers, packaging vendors, and pharma equipment service centres are all local, so lead times and machine downtime stay short.
• A GMP-trained talent pool. Three decades of pharma manufacturing in the BBN belt means operators, QA/QC analysts, and documentation staff are available without a long hiring-and-training runway.
• Regulatory familiarity. Local consultants and the state licensing authority handle CDSCO and Himachal drug-control work routinely, which shortens transfers and approvals.
• Connectivity. Baddi sits roughly 45 minutes from Chandigarh, 30 minutes from Panchkula, and about 4.5 hours from Delhi — practical for inbound raw material and outbound distribution.

The same unit in a non-cluster location usually means slower buying, higher compliance cost, and a longer recruitment cycle. In Baddi, everything you need is already close by.

Freehold ownership matters here. As larger players buy up land across Baddi, clear-title freehold plots are getting scarcer, and the land carries its own appreciation potential. The 78,000 sq ft built-up area on a 3,000 sq m plot is sized for efficient operation with room to add lines — you are not paying for idle space.

Over 1,000 formulations across four dosage forms. Output per 8-hour shift:

Multi-form flexibility is a real commercial advantage: if a client shifts from tablets to capsules, or a segment softens, output can be re-mixed without changing the facility. For a third-party manufacturer, that is revenue diversification and client retention in one.

The figures below are as represented by the seller and must be checked in diligence:

• Revenue: ₹100+ crore/year. At 350 staff, that is about ₹28.6 lakh revenue per employee — inside the normal ₹25–35 lakh band for Indian pharma manufacturing, so the unit is properly staffed, not overstaffed.
• EBITDA margin: 15–25%. Listed third-party manufacturers usually run mid-teens to low-twenties, so this range is competitive rather than exceptional. The spread reflects seasonal utilisation and product mix.
• 400+ third-party clients. This is the real advantage. Third-party relationships are sticky because moving a product to a new site means re-validation — usually 6–12 months and ₹20–50 lakh for the customer — which protects both retention and modest pricing power.

1. Third-party manufacturing demand is structural. India is a global hub for generics and APIs, and outsourcing keeps rising — startups avoid ₹2–5 crore of capex by using contract manufacturers, and larger firms hand off commoditised products to free up capital. A ready Baddi unit serves that demand at once; a greenfield build sits out the first 18–24 months while competitors take it. (See the loan-licence and third-party manufacturing models for how buyers use spare capacity.)

2. Schedule M compliance is now enforced — and that favours a compliant unit. The revised Schedule M was notified in December 2023 and took effect on 1 January 2025. The extension window for smaller manufacturers closed on 31 December 2025, and CDSCO is now running risk-based inspections with no further blanket extensions signalled. Non-compliant units face retrofits of roughly ₹0.5–1.5 crore per line plus downtime; this facility is already compliant, so that cost and disruption do not apply. As enforcement tightens across Baddi, compliant capacity gains share.

3. Export room through the WHO-GMP route. The unit exports to a handful of RoW markets today — a small share of what WHO-GMP-accepting markets allow. Moving into more RoW / semi-regulated markets, applying for WHO prequalification on suitable products, and entering tender/donor supply are all realistic growth options on the existing certifications. (Pricing varies widely by market and product; treat any per-unit figures as indicative only.)

At the conservative case — ₹100 crore revenue, 15% EBITDA, ₹0.75 crore maintenance & compliance — the unit produces about ₹14.25 crore of unlevered operating cash flow, roughly a 28% cash yield on ₹51 crore before any debt.

Add debt and the return on your equity changes — model it with a proper amortising EMI, not a flat estimate. A fully-amortising ₹51 crore loan at 8% over 5 years costs about ₹12.4 crore/year, with year-one interest alone around ₹4.1 crore. Use the pharma plant cost calculator to compare this against a greenfield build.

On valuation: at ₹18 crore EBITDA (an 18% midpoint), ₹51 crore is about 2.8× EBITDA — below the 3–4× comparable units usually fetch. That discount fits a motivated relocation sale rather than a stretched ask, which is part of what makes it worth moving on.

These figures are illustrative, exclude tax and working-capital movements, and do not constitute investment advice. Check all inputs independently.

Working in your favour: a proven, diversified client base with high switching costs; multi-dosage flexibility; certifications already in place; a trained workforce you take over rather than build; and a brownfield asset with no construction or environmental-cleanup unknowns.

What you are taking on:

None of these is fatal with active management — but this is an operating business, not a passive holding.

Before committing capital, check the fundamentals across five workstreams. Budget roughly ₹20–35 lakh in advisory costs and 4–5 months end to end.

• Financial (weeks 3–5): 3 years’ audited P&L reconciled against GST filings and bank statements; cost structure (raw material usually 40–50% of revenue); working-capital ageing; contingent liabilities. Red flag: a P&L that does not tie to GST.
• Operational (weeks 4–6): independent equipment audit (age, condition, service history — relevant given the 2016 build); capacity validation against actual batch records; QC lab adequacy (HPLC, dissolution, method validation per USP/BP); OOS history. Red flag: OOS >2%, or nameplate capacity that demonstrated runs don’t support.
• Regulatory (week 5): WHO-GMP scope, validity and inspection history; CDSCO licence status and scope; DCGI product approvals; environmental clearances (ETP, hazardous-waste disposal). Red flag: expired certs or open observations.
• Customer (weeks 6–7): top-10 concentration (ideally no single cluster >50%); contract terms and renewals; 5–10 quiet client interviews on quality, reliability, and intent to continue post-sale; churn history. Red flag: >15% annual churn, or churn tied to quality.
• Legal & ownership (weeks 5–8): title verification (freehold, no encumbrances); authority to sell; change-of-control clauses in customer, supplier, and financing contracts; pending litigation. Red flag: material contracts that terminate on change of control.

A 30–90 day handover with the outgoing team and key-customer introductions is standard.

Acquisition fits if you want returns inside 3–4 years, cannot wait ~2 years for a build, and value taking over a working team and client book. Greenfield fits only if you need IP-specific manufacturing, want to design the plant from scratch, and have deep pharma-operations experience plus a long horizon. For most buyers, acquisition is the lower-risk path.

A site visit is essential; you cannot judge a facility from documents alone. Plan a full day — 3–4 hours on the floor (all production areas, QC lab, warehouse, utilities) and 2 hours with senior management — and bring an operations advisor and an accountant.

When you make contact, ask for: audited financials (3 years); WHO-GMP certificate (scope + expiry); CDSCO manufacturing licence (scope + status); top-20 client list with revenue contribution; equipment schedule; a capacity study backed by batch records; environmental-compliance documents; and a proposed transition timeline.